Nuwellis, Inc.

NUWE Healthcare Medical Devices

Nuwellis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.3 million, down 5.38% from fiscal 2024. In the quarter to June 2026, revenue grew 14.1%, EPS grew 98.8% and free cash flow fell 51.6%, each against the same quarter a year earlier.

0.55 0.00 0.00%
Market cap
$2.0M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
3/9
Altman Z
−76.39
Beneish M
−7.71
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 3 3 3
ROE
(467.58%) (382.80%) (610.45%) 205.50%
ROA
(225.18%) (219.21%) (272.69%) (123.52%)
ROIC
(848.43%) (449.27%) (1,345.35%) 0.00%
Return on Tangible Assets
(404.79%) (694.57%) (773.48%) (267.06%)
Average Days of Receivables
50.99 65.89 64.89 62.57
Free Cash Flow per Share
(393.01) (554.47) (195.55) (69.97)
Free Cash Flow
(9.39) (10.92) (11.60) (12.68)
Capital Expenditures
(0.11) (0.11) (0.21) (0.21)
Other line items
Cash ROIC
(134.15%) (294.02%) (244.02%) (675.49%)
Accounts Receivable Turnover
6.71 5.14 5.66 6.58
Accounts Payable Turnover
1.49 1.63 1.46 0.93
Inventory Turnover
1.65 1.73 1.72 1.45
Average Days of Payables
291.30 258.26 292.80 386.91
Days of Inventory on Hand
239.00 221.60 214.44 232.73
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
32.55% 32.79% 44.36% 46.12%
Selling, General and Administrative Expense of Revenue
161.80% 163.46% 164.96% 166.44%
Share Based Compensation of Revenue
2.53% 1.54% 0.97% 1.00%
Interest Coverage
— — — (0.58)
Operating CF/Net income
0.56 0.62 0.60 1.10
Depreciation/Fixed assets
0.63 0.54 0.45 0.44
Capex/Depreciation
(0.42) (0.56) (1.27) (1.41)
Revenue per Share
341.76 419.80 147.88 49.74
Operating CF per Share
(388.45) (548.73) (192.01) (68.79)
Capex per Share
(4.56) (5.74) (3.54) (1.19)
Capex to Sales
0.01 0.01 0.02 0.02

Fold the line items

Columns are period end dates